Iran Faces Severe Drug Shortages and Skyrocketing Prices for Critical Medications

Citizens in Iran are facing a critical healthcare crisis characterized by severe shortages and price hikes of up to 400 percent for essential medications. Reports indicate that patients with chronic and life-threatening conditions, including cancer, organ transplants, epilepsy, and psychiatric disorders, are disproportionately affected. Many individuals struggle to find prescribed drugs, often visiting numerous pharmacies daily without success, leading some to resort to black markets or ineffective herbal alternatives recommended by pharmacists. The situation is exacerbated by insurance companies' failure to settle payments with pharmacies, forcing many drugs onto the free market at prohibitive costs. Specific examples include the unavailability of Rapamune for transplant recipients, which risks organ rejection, and drastic price increases for insulin, psychiatric drugs like Asentra, and cancer treatments such as Erbitux. Residents describe the scenario as a regression to pre-modern medical practices, with basic painkillers and vaccines also seeing significant price surges. The crisis threatens the lives of vulnerable populations who cannot afford or access necessary treatments, highlighting systemic failures in the country's pharmaceutical supply chain and healthcare financing.